These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27993846)

  • 1. Nonnucleoside Reverse Transcriptase Inhibitors Reduce HIV-1 Production from Latently Infected Resting CD4
    Zerbato JM; Tachedjian G; Sluis-Cremer N
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages.
    Hany L; Turmel MO; Barat C; Ouellet M; Tremblay MJ
    J Virol; 2022 Feb; 96(4):e0195321. PubMed ID: 34878918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD32 expression is associated to T-cell activation and is not a marker of the HIV-1 reservoir.
    Badia R; Ballana E; Castellví M; García-Vidal E; Pujantell M; Clotet B; Prado JG; Puig J; Martínez MA; Riveira-Muñoz E; Esté JA
    Nat Commun; 2018 Jul; 9(1):2739. PubMed ID: 30013105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
    Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
    PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1.
    López-Huertas MR; Jiménez-Tormo L; Madrid-Elena N; Gutiérrez C; Rodríguez-Mora S; Coiras M; Alcamí J; Moreno S
    Sci Rep; 2017 May; 7(1):2385. PubMed ID: 28539614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents.
    Marsden MD; Wu X; Navab SM; Loy BA; Schrier AJ; DeChristopher BA; Shimizu AJ; Hardman CT; Ho S; Ramirez CM; Wender PA; Zack JA
    Virology; 2018 Jul; 520():83-93. PubMed ID: 29800728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication.
    Marsden MD; Loy BA; Wu X; Ramirez CM; Schrier AJ; Murray D; Shimizu A; Ryckbosch SM; Near KE; Chun TW; Wender PA; Zack JA
    PLoS Pathog; 2017 Sep; 13(9):e1006575. PubMed ID: 28934369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Combination of Venetoclax and Ixazomib Selectively and Efficiently Kills HIV-Infected Cell Lines but Has Unacceptable Toxicity in Primary Cell Models.
    Alto A; Natesampillai S; Chandrasekar AP; Krogman A; Misra A; Shweta F; VanLith C; Yao JD; Cummins NW; Badley AD
    J Virol; 2021 May; 95(12):. PubMed ID: 33827940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal.
    Martínez-Bonet M; Clemente MI; Álvarez S; Díaz L; García-Alonso D; Muñoz E; Moreno S; Muñoz-Fernández MÁ
    Antiviral Res; 2015 Nov; 123():163-71. PubMed ID: 26427554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 blockade potentiates HIV latency reversal ex vivo in CD4
    Fromentin R; DaFonseca S; Costiniuk CT; El-Far M; Procopio FA; Hecht FM; Hoh R; Deeks SG; Hazuda DJ; Lewin SR; Routy JP; Sékaly RP; Chomont N
    Nat Commun; 2019 Feb; 10(1):814. PubMed ID: 30778080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed.
    Rezaei SD; Lu HK; Chang JJ; Rhodes A; Lewin SR; Cameron PU
    J Virol; 2018 Jul; 92(13):. PubMed ID: 29643247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.
    Laird GM; Bullen CK; Rosenbloom DI; Martin AR; Hill AL; Durand CM; Siliciano JD; Siliciano RF
    J Clin Invest; 2015 May; 125(5):1901-12. PubMed ID: 25822022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.
    Bullen CK; Laird GM; Durand CM; Siliciano JD; Siliciano RF
    Nat Med; 2014 Apr; 20(4):425-9. PubMed ID: 24658076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective BCL-X
    Ren Y; Huang SH; Macedo AB; Ward AR; Alberto WDC; Klevorn T; Leyre L; Copertino DC; Mota TM; Chan D; Truong R; Rohwetter T; Zumbo P; Dündar F; Betel D; Kovacs C; Benko E; Bosque A; Jones RB
    J Virol; 2021 Jul; 95(15):e0242520. PubMed ID: 33980597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Approaches to Eradicate Latent HIV-1 in Resting CD4+ T Cells.
    Sluis-Cremer N
    Curr Top Med Chem; 2016; 16(10):1191-7. PubMed ID: 26324046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy.
    Blazkova J; Chun TW; Belay BW; Murray D; Justement JS; Funk EK; Nelson A; Hallahan CW; Moir S; Wender PA; Fauci AS
    J Infect Dis; 2012 Sep; 206(5):765-9. PubMed ID: 22732922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. G-quadruplex ligands targeting telomeres do not inhibit HIV promoter activity and cooperate with latency reversing agents in killing latently infected cells.
    Piekna-Przybylska D; Bambara RA; Maggirwar SB; Dewhurst S
    Cell Cycle; 2020 Sep; 19(18):2298-2313. PubMed ID: 32807015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
    Mousseau G; Kessing CF; Fromentin R; Trautmann L; Chomont N; Valente ST
    mBio; 2015 Jul; 6(4):e00465. PubMed ID: 26152583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.